ES2107431T3 - Agentes con accion selectiva sobre los receptores de la adenosina. - Google Patents

Agentes con accion selectiva sobre los receptores de la adenosina.

Info

Publication number
ES2107431T3
ES2107431T3 ES91104668T ES91104668T ES2107431T3 ES 2107431 T3 ES2107431 T3 ES 2107431T3 ES 91104668 T ES91104668 T ES 91104668T ES 91104668 T ES91104668 T ES 91104668T ES 2107431 T3 ES2107431 T3 ES 2107431T3
Authority
ES
Spain
Prior art keywords
adenosine
agents
adenosine receptors
selective action
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91104668T
Other languages
English (en)
Inventor
Norton P Peet
Nelsen L Lentz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2107431T3 publication Critical patent/ES2107431T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCUBREN, DERIVADOS DE XANTINA QUE SON SELECTIVAMENTE RECEPTORES DE ADENOSINA Y QUE ACTUAN EN GENERAL COMO ANTAGONISTAS DE ADENOSINA. SE CONOCE POR ESTUDIOS "IN VITRO" QUE EFECTOS ESPECIFICOS FISIOLOGICOS SE PUEDEN DISTINGUIR COMO UN RESULTADO DE ESTA SELECTIVIDAD Y QUE LA ACTIVIDAD RECEPTORA DE ADENOSINA "IN VITRO" SE CORELACIONA CON LA ACTIVIDAD RECEPTORA DE ADENOSINA "IN VIVO". SE PUEDEN PREPARAR PREPARACIONES FARMACEUTICAS DE ESTOS COMPUESTOS EN BASE A LA ACTIVIDAD DE ENLACE SELECTIVA DE LOS COMPUESTOS DESCUBIERTOS AQUI QUE REALZARAN CIERTOS EFECTOS FISIOLOGICOS MIENTRAS MINIMIZAN OTROS, TAL COMO DISMINUIR LA PRESION SANGUINEA SIN DISMINUIR LA PRODUCCION CARDIACA.
ES91104668T 1990-03-26 1991-03-25 Agentes con accion selectiva sobre los receptores de la adenosina. Expired - Lifetime ES2107431T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/499,111 US5047534A (en) 1990-03-26 1990-03-26 Selective adenosine receptor agents

Publications (1)

Publication Number Publication Date
ES2107431T3 true ES2107431T3 (es) 1997-12-01

Family

ID=23983864

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91104668T Expired - Lifetime ES2107431T3 (es) 1990-03-26 1991-03-25 Agentes con accion selectiva sobre los receptores de la adenosina.

Country Status (22)

Country Link
US (1) US5047534A (es)
EP (1) EP0449175B1 (es)
JP (1) JP3181305B2 (es)
KR (1) KR100195368B1 (es)
CN (1) CN1032815C (es)
AR (1) AR247887A1 (es)
AT (1) ATE156130T1 (es)
AU (1) AU632914B2 (es)
CA (1) CA2038747C (es)
DE (1) DE69127010T2 (es)
DK (1) DK0449175T3 (es)
ES (1) ES2107431T3 (es)
FI (1) FI98461C (es)
GR (1) GR3025135T3 (es)
HU (1) HU208824B (es)
IE (1) IE910982A1 (es)
IL (1) IL97656A (es)
NO (1) NO177591C (es)
NZ (1) NZ237484A (es)
PH (1) PH27511A (es)
PT (1) PT97133B (es)
ZA (1) ZA912038B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
PT628311E (pt) * 1992-07-08 2002-09-30 Kyowa Hakko Kogyo Kk Derivado de xantina com actividade antidepressiva
WO1994019349A1 (en) * 1993-02-26 1994-09-01 Merrell Dow Pharmaceuticals Inc. Xanthine derivatives as adenosine a1 receptor antagonists
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
CA2159989C (en) * 1993-05-06 1994-11-24 Norton P. Peet 8-substituted xanthines as selective adenosine receptor agents
US5629298A (en) * 1995-03-13 1997-05-13 University Of Massachusetts Medical Center Adenosine as a positive inotrop in the compromised heart
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
US6258794B1 (en) 1999-12-14 2001-07-10 The Mclean Hospital Corporation Treatment of mental conditions including depression
ATE481101T1 (de) 2003-06-10 2010-10-15 Kyowa Hakko Kirin Co Ltd Verfahren zur behandlung von angstzuständen
WO2007036491A1 (de) * 2005-09-30 2007-04-05 Basf Aktiengesellschaft Verfahren zur herstellung von alpha-substituierten carbonsäuren
US7592461B2 (en) * 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1435916A (en) * 1972-05-11 1976-05-19 Beecham Group Ltd Pharmaceutical weight-reducing compositions
SE416810C (sv) * 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
JPS57198544A (en) * 1981-05-28 1982-12-06 Sony Corp Manufacture of magnetic recording medium
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung

Also Published As

Publication number Publication date
JPH04221384A (ja) 1992-08-11
AR247887A1 (es) 1995-04-28
CA2038747A1 (en) 1991-09-27
IL97656A0 (en) 1992-06-21
IE910982A1 (en) 1991-10-09
NO911200D0 (no) 1991-03-25
NO177591C (no) 1995-10-18
EP0449175A2 (en) 1991-10-02
FI911420A0 (fi) 1991-03-25
CN1032815C (zh) 1996-09-18
NO177591B (no) 1995-07-10
FI98461B (fi) 1997-03-14
DK0449175T3 (da) 1998-02-23
CA2038747C (en) 2002-05-28
ZA912038B (en) 1991-12-24
PH27511A (en) 1993-08-18
GR3025135T3 (en) 1998-02-27
JP3181305B2 (ja) 2001-07-03
NZ237484A (en) 1993-10-26
DE69127010T2 (de) 1997-11-13
KR910016752A (ko) 1991-11-05
IL97656A (en) 1996-06-18
FI98461C (fi) 1997-06-25
AU632914B2 (en) 1993-01-14
ATE156130T1 (de) 1997-08-15
HUT56570A (en) 1991-09-30
EP0449175B1 (en) 1997-07-30
NO911200L (no) 1991-09-27
US5047534A (en) 1991-09-10
KR100195368B1 (ko) 1999-06-15
PT97133B (pt) 1998-07-31
DE69127010D1 (de) 1997-09-04
FI911420L (fi) 1991-09-27
AU7353791A (en) 1991-10-03
PT97133A (pt) 1991-12-31
CN1055181A (zh) 1991-10-09
EP0449175A3 (en) 1993-01-20
HU208824B (en) 1994-01-28

Similar Documents

Publication Publication Date Title
LU91449I2 (fr) "panitumumab en combinaison avec un agent anti-néoplastique"
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
ES2138977T3 (es) Agonistas muscarinicos.
ES2052704T3 (es) Analogos de benzodiacepina.
MX9201730A (es) Nuevos fenilazacicloalcanos substituidos que actuan centralmente.
FI880509A7 (fi) LHRH:n nonapeptidi- ja dekapeptidianalogeja, jotka ovat käyttökelpoisia LHRH:n antagonisteina
IT8720650A0 (it) Derivati dell'etere immidazochinolinilico ad azione farmaceutica e procedimento per laloro preparazione.
MX9203026A (es) Enantiomero dextrogiro del alfa-(tetrahidro-4,5,5-tieno (3,2-c) piridil-5) (cloro-2 fenil)-acetato de metilo y composiciones farmaceuticas que lo contienen.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
ES2107431T3 (es) Agentes con accion selectiva sobre los receptores de la adenosina.
AR004545A1 (es) Derivados de purin-6-ona, procedimientos para su preparacion, el uso de los mismos en la preparacion de medicamentos, medicamentos que los contieneny un procedimiento para preparar dichos medicamentos
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
CA2013380A1 (en) Selective adenosine receptor agents
ES2117654T3 (es) Antagonistas de colecistoquinina.
DK0686155T3 (da) Xanthinderivater som adenosin A1-receptor-antagonister
ES2037709T3 (es) Derivados heterociclicos de seis miembros de n,n'-diacilhidrazinas n'-sustituidas.
ES2044100T3 (es) Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.
ES2086195T3 (es) Nuevos derivados pseudopeptidicos de actividad antagonista de la bradiquinina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2060944T3 (es) Derivados de 2,5,6,7-tetranor-4,8-inter-m-fenileno de pgi2 (prostaglandina i2).
ES2093612T3 (es) Neoglucoproteinas, su preparacion y empleo.
ES2072869T3 (es) Uso de derivados de la 1,4-dihidropiridina en el tratamiento del alcoholismo.
ES2102679T3 (es) Adenosinas 2-sustituidas con afinidad de receptor a-2.
DK0427827T3 (da) 8alfa-acylaminoergoliner, deres fremstilling og anvendelse som lægemiddel.
ES2063851T3 (es) Compuestos con accion selectiva sobre receptores de adenosina.
AR247200A1 (es) Procedimiento para preparar una nueva clase de agentes medicinales piperidinilicos, utiles como agentes antitromboticos y como antagonistas de los receptores de 5ht2 de serotonina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 449175

Country of ref document: ES